Review

Is radical cystectomy the gold standard?
  • Binhan Kağan Aktaş
  • Ali Memiş
Bull Urooncol 2013; 12: 1-5
Bladder cancer epidemiology in the world and in Tukey
  • Sultan Eser
  • Raziye Özdemir
Bull Urooncol 2012; 11: 1-9
The developments in paradigm of prostate cancer in recent years
  • Sertaç Yazıcı
  • Halil Kızılöz
  • Haluk Özen
Bull Urooncol 2014; 13: 1-7
Prognostic factors in renal cancer and prediction models
  • Ümit Gül
  • Özgür Yaycıoğlu
Bull Urooncol 2011; 10: 5-10
PSA: past, today and tomorrow
  • Levent Mert Günay
  • Sertaç Yazıcı
  • Haluk Özen
Bull Urooncol 2011; 10: 5-10
Robotic surgery in radical cystectomy
  • Yakup Kordan
  • Burhan Coşkun
Bull Urooncol 2013; 12: 6-10
An update on palliative therapy in advanced prostate cancer
  • Kaan Özdedeli
  • Uğur Kuyumcuoğlu
Bull Urooncol 2014; 13: 8-14
Genetik alteration in bladder carcinoma
  • Hakan Akça
  • Onur Tokgün
Bull Urooncol 2012; 11: 10-13
Geometry of cancer and fractals in bladder cancer
  • Fehmi Narter
  • Osman Köse
Bull Urooncol 2013; 12: 11-17
New approaches to assess the morphology of renal masses
  • Barbaros Başeskioğlu
  • Cavit Can
Bull Urooncol 2011; 10: 11-15
Current analysis of urinary biomarkers for prostate cancer
  • Faruk Yencilek
  • Hakan Koyuncu
Bull Urooncol 2011; 10: 11-16
Positron Emission Tomography/Computed Tomography in Bladder Carcinoma
  • Recep Bekiş
  • Emine Acar
  • Uğur Mungan
Bull Urooncol 2015; 14: 13-17 DOI: 10.4274/uob.236
The approaches in uncommon malignant tumours of the bladder
  • Hayrettin Şahin
Bull Urooncol 2012; 11: 14-18
Prostate cancer, screening and diagnosis according to EAU and AUA 2013 updates and practical considerations
  • Tünkut Doğanca
  • Can Öbek
Bull Urooncol 2014; 13: 15-20
Biopsy of renal mass: The past, present and the future
  • Tünkut Doğanca
  • Can Öbek
Bull Urooncol 2011; 10: 16-20
Can prostate cancer be prevented?
  • İlkan Yüksel
  • Mustafa Kaplan
Bull Urooncol 2011; 10: 17-21
The Relationship between Bladder Cancer and Epigenetic Alterations
  • Ata Özen
  • Ali Ülgen
  • Cavit Can
Bull Urooncol 2017; 16: 17-21 DOI: 10.4274/uob.566
BCG suşlarının tedavi edici etkinlik farkı var mı?
  • Hayrettin Şahin
Bull Urooncol 2011; 10: 18-20
The Risk Stratifications in Non-Muscle Invasive Bladder Cancer: How Much Accurate are the Methods That We Use? A Multi-Directional View
  • Barış Kuzgunbay
  • Yıldırım Bayazıt
Bull Urooncol 2015; 14: 18-22 DOI: 10.4274/uob.275
İdame BCG kime uygulanmalı nasıl uygulanmalı?
  • Çetin Volkan Öztekin
  • Veli Erşahin
Bull Urooncol 2011; 10: 21-22
The role of surgery for high-risk prostate cancer
  • Oktay Üçer
  • Talha Müezzinoğlu
Bull Urooncol 2014; 13: 21-24
Is intravesical BCG treatment necessary and/or sufficient?
  • Sinan Ekici
  • Polat Türker
Bull Urooncol 2013; 12: 22-25
Does inhibition of inflammation help in preventing prostate cancer ?
  • Ali İhsan Arık
  • Ahmet Güdeloğlu
  • Cemil Uygur
Bull Urooncol 2011; 10: 22-26
The Role of Radiology in Perivesical Invasion of Muscle-Invasive Bladder Cancer
  • İbrahim İlker Öz
  • Aydın Mungan
Bull Urooncol 2016; 15: 22-25 DOI: 10.4274/uob.550
Does the Future of Prostate Cancer Treatment Lie with Apoptotic Inducers?
  • Dr. Ece Konaç
  • Dr. Sinan Sözen
Bull Urooncol 2017; 16: 22-27 DOI: 10.4274/uob.606
BCG komplikasyonları ve başa çıkma
  • Uğur Yücetaş
  • Gökhan Toktaş
Bull Urooncol 2011; 10: 23-25
Radical Cystectomy in Elderly Patients: Predicting Complications and Mortality, Technical Aspects and Postoperative Care
  • Uğur Kuyumcuoğlu
  • Kaan Özdedeli
Bull Urooncol 2015; 14: 23-28 DOI: 10.4274/uob.280
Lympadenectomy in prostate cancer
  • Murat Koşan
Bull Urooncol 2014; 13: 25-28
Which Patients Should Undergo Immediate or Deferred Cystectomy in Non-Muscle Invazive Bladder Cancer? Evaluation of...
  • Şenol Tonyalı
  • Mustafa Sertaç Yazıcı
Bull Urooncol 2016; 15: 26-30 DOI: 10.4274/uob.536
The effect of trace elements in prostate cancer
  • İlker Çelen
  • Feriye Şenol
  • Talha Müezzinoğlu
Bull Urooncol 2011; 10: 27-32
Comparing outcomes of external radiotherapy modalities for prostate cancer
  • Şefik İğdem
Bull Urooncol 2014; 13: 29-32
Experimental Bladder Cancer Models for Animals
  • Murat Koşan
  • Aydın Mungan
Bull Urooncol 2015; 14: 29-32 DOI: 10.4274/uob.283
Should all patients with non-muscle invaziv bladder tumor receive postoperative early single dose intravesical chemotherapy?
  • Sümer Baltacı
  • Ömer Gülpınar
Bull Urooncol 2012; 11: 30-33
Limited-standard-extended lymphadenectomy in bladder cancer
  • Hayrettin Şahin
Bull Urooncol 2013; 12: 31-35
Synchronous and Metachronous Secondary Tumors of Bladder Cancer Patients
  • Ayhan Dirim
  • Hakan Özkardeş
  • Eray Hasırcı
Bull Urooncol 2016; 15: 31-37 DOI: 10.4274/uob.545
Has DNA methylation any impact in prostate cancer diagnosis?
  • Buket Kosova
  • Rukiye Özel
  • Çağdaş Aktan
Bull Urooncol 2011; 10: 33-40
In which fields intermittent androgen deprivation therapy can be used in 2014?
  • Yasin Ceylan
  • Bu¨lent Gu¨nlu¨soy
Bull Urooncol 2014; 13: 33-36
Approach to the complications of intravesical therapy in bladder cancer
  • Turgay Gülecen
  • Cüneyd Özkürkçügil
Bull Urooncol 2012; 11: 34-40
Dev Ta Tümörde TUR nasıl Yapılmalıdır?
  • Taylan Oksay
Bull Urooncol 2011; 10: 35-37
Bladder cancer and genetics
  • Ata Özen
  • Cavit Can
Bull Urooncol 2013; 12: 36-42
Surgery in metastatic renal cell carcinoma
  • Volkan İzol
  • Bülent Soyupak
Bull Urooncol 2011; 10: 36-40
TUR'a bağlı mesane perforasyonu: tedavi ve izlem
  • Kürsad Zengin
  • Sinan Başay
Bull Urooncol 2011; 10: 38-40
Screening for Bladder Cancer: Reliability and Limitations
  • Kamil Fehmi Narter
  • Cahit Şahin
Bull Urooncol 2015; 14: 38-45 DOI: 10.4274/uob.238
Recent advancements in the targeted therapy of metastatic kidney cancer
  • Sertaç Yazıcı
  • Halil Kızılöz
  • Haluk Özen
Bull Urooncol 2011; 10: 41-51
Active Surveillance: Treatment Modality that Expect Attention for Localized Prostate Cancer
  • Tayyar Alp Özkan
  • Özdal Dillioğlugil
Bull Urooncol 2014; 13: 41-45
Nursing care following radical cystectomy and urinary diversion
  • Cemile Ulubay Akkaya
Bull Urooncol 2013; 12: 43-45
Is it possible to predict BCG effectivity in the treatment of superficial bladder cancer? Are there any markers?
  • Polat Türker
  • Sinan Ekici
Bull Urooncol 2012; 11: 46-51
History of Urologic Oncology in Turkey: Bladder Cancers
  • Yaşar Bedük
Bull Urooncol 2015; 14: 46-49 DOI: 10.4274/uob.295
A critical analysis of surgical curative treatments options in localised prostate cancer: open, laparoscopic, and robotassisted radical prostatectomy
  • Ender Özden
  • Yakup Bostancı
  • Yarkın Kamil Yakupoğlu
Bull Urooncol 2011; 10: 47-50
Genişletilmiş lenfadenektomi standart bir tedavi olmalı mı?
  • Ömer Gökhan Doluoğlu
  • Mehmet Karabakan
Bull Urooncol 2011; 10: 48-50
Experimental animal models for bladder cancer
  • Şevket Tolga Tombul
  • Talha Müezzinoğlu
Bull Urooncol 2013; 12: 50-53
The role of 5α-reductase inhibitors on prevention and hormonal treatment of prostate cancer
  • Bülent Öztürk
  • Tufan Çiçek
Bull Urooncol 2014; 13: 50-53
Non-Muscle Invasive Bladder Cancer: Diagnosis and Treatment of Highest-Risk Subgroup
  • Yılören Tanıdır
  • İlker Tınay
Bull Urooncol 2015; 14: 50-54 DOI: 10.4274/uob.298
Algorithmic approach to rising PSA after curative prostate cancer treatment
  • Levent Mert Günay
  • Şevket Tolga Tombul
  • Bülent Akdoğan
Bull Urooncol 2011; 10: 51-55
Açık, laparoskopik ve robotik sistektomi: avantaj ve dezavantajları
  • Bülent Altunoluk
Bull Urooncol 2011; 10: 51-54
The Role of Imaging in Testicular Cancer Diagnosis, Staging and Follow-up
  • Nuray Voyvoda
  • Bekir Voyvoda
  • Özden Çamurdan
Bull Urooncol 2017; 16: 51-56 DOI: 10.4274/uob.694
Radiological methods that aid in the diagnosis of bladder cancer
  • Fatih Kantarcı
  • Deniz Çebi Olgun
  • Atilla Süleyman Dikici
Bull Urooncol 2013; 12: 54-57
The influence of age on localized prostate cancer: Surgical result of patients over 70 years
  • Erdal Benli
  • Ali Ayyıldız
Bull Urooncol 2014; 13: 54-57
Can Bladder be Preserved with TURB + Chemotherapy instead of Radical Surgery (Can we Preserve the Bladder from Cancer)
  • Cavit Can
Bull Urooncol 2012; 11: 55-57
Quality of Life after Radical Cystectomy and Diversion
  • Gökhan Toktaş
  • Emre Karabay
Bull Urooncol 2015; 14: 55-60 DOI: 10.4274/uob.299
Could focal therapy in prostate cancer replace standard therapy in the future?
  • Saadettin Y. Eskiçorapçı
  • Cihan Toktaş
Bull Urooncol 2011; 10: 56-62
Risk Adaptive Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
  • Elif Atağ
  • Aziz Karaoğlu
  • Ömer Küçük
Bull Urooncol 2017; 16: 57-62 DOI: 10.4274/uob.763
Neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
  • Aziz Karaoğlu
  • Utku Oflazoğlu
  • Necla Demir
Bull Urooncol 2013; 12: 58-63
Outstanding variations in the treatment of prostate cancer bone metastases
  • İbrahim Cüreklibatır
Bull Urooncol 2014; 13: 58-62
Role of Nanoparticles in the Treatment of Noninvasive Bladder Cancer
  • Erem Bilensoy
  • Nazlı Erdoğar
  • Aydın N. Mungan
Bull Urooncol 2015; 14: 61-66 DOI: 10.4274/uob.246
Neoadjuvant and adjuvant treatment modalities for prostate cancer
  • Erkan Erkan
  • Gökhan Toktaş
Bull Urooncol 2011; 10: 63-69
How affected Active Surveillance the quality of life in low-risk localized prostate cancer?
  • İlker Çelen
  • Sinharib Çitgez
  • Talha Müezzinoğlu
Bull Urooncol 2014; 13: 63-66
The importance of cellular androgenic hormonal mechanisms in treatment and progression of prostate cancer
  • Bertrand Tombal
Bull Urooncol 2013; 12: 65-70
A New Era in Metastatic Prostate Cancer: “The Combination of Chemotherapy and Hormonal Treatment as Initial Treatment”
  • İlker Tinay
  • Levent Türkeri
Bull Urooncol 2016; 15: 65-68 DOI: 10.4274/uob.434
Targeted Therapies in Metastatic Bladder Cancer: Has It Been Approved as a Treatment Option Nowadays?
  • Nil Molinas Mandel
Bull Urooncol 2015; 14: 67-70 DOI: 10.4274/uob.2015.14.001
Management of post-chemotherapy residual masses in testicular tumor and surgical tecnique
  • Ferhat Ateş
  • Ömer Yılmaz
  • Kadir Vehbi Baykal
Bull Urooncol 2011; 10: 68-74
Sentinel Lymph Node Biopsy in Lymphadenectomy for Prostate Cancer
  • Cenk Acar
  • Henk van der Poel
Bull Urooncol 2016; 15: 69-75 DOI: 10.4274/uob.625
What is the evidence-based ideal treatment of clinical locally advanced (cT3) prostate cancer?
  • Asıf Yıldırım
  • Erem Kaan Başok
Bull Urooncol 2011; 10: 70-75
Is prostate cancer be screened according to Turkey data?
  • Rahmi Gökhan Ekin
  • Ferruh Zorlu
Bull Urooncol 2013; 12: 71-75
Surgical Approaches in Patients with Metastatic Bladder Cancer: Metastasectomy and Palliative Cystectomy
  • Utku Lokman
  • Özgür Uğurlu
Bull Urooncol 2014; 13: 75-78 DOI: 10.4274/UOB.03
Active surveillance in low risk prostate cancer
  • Ozan Bozkurt
  • Ömer Demir
Bull Urooncol 2013; 12: 76-79
Hormonal treatment of metastatic prostate cancer: Today and future
  • Hasan Soydan
  • Kadir Baykal
Bull Urooncol 2011; 10: 76-81
Magnetic Resonance - Transrectal Ultrasound Fusion Guided Prostate Biopsy
  • Ömer Burak Argun
  • Can Öbek
  • Ali Rıza Kural
Bull Urooncol 2016; 15: 76-79 DOI: 10.4274/uob.635
Approaches to Upper Urinary Tract Recurrences Following Radical Cystectomy
  • Mehmet İlker Gökçe
  • Sümer Baltacı
Bull Urooncol 2014; 13: 79-83 DOI: 10.4274/UOB.04
Treatment options in low-intermediate risk prostate cancer
  • Saadettin Yılmaz Eskiçorapçı
  • Deniz Bolat
Bull Urooncol 2013; 12: 80-85
Robotic assisted laparoscopic surgery for the treatment of kidney cancer:current status in 2011
  • Cihan Toktaş
  • Saadettin Eskiçorapçı
Bull Urooncol 2011; 10: 82-85
Immunotherapy in prostate cancer
  • Murat Lekili
Bull Urooncol 2011; 10: 82-84
Comparison of the Clinical and Pathologic Staging in Patients Undergoing Radical Cystectomy, the Factors Associated with Upstaging and its Effect on Outcome
  • Polat Türker
Bull Urooncol 2014; 13: 84-87 DOI: 10.4274/UOB.05
Nomograms for prostate cancer: which and when to use
  • Saadettin Eskiçorapçı
  • Deniz Bolat
Bull Urooncol 2012; 11: 85-91
Are there any treatment option for metastatic prostate cancer refractory to docetaksel?
  • Yaşar Bedük
Bull Urooncol 2011; 10: 85-89
Radiotherapy in low and intermediate-risk prostate cancer
  • Deniz Yalman
Bull Urooncol 2013; 12: 86-91
Transurethral Resection of Bladder Cancer (TUR-B) for Non-Muscle Invasive Bladder Cancer: How to Reach Excellence?
  • Mehmet İlker Gökçe
  • Yaşar Bedük
Bull Urooncol 2014; 13: 88-92 DOI: 10.4274/UOB.06
Recommendations of Diet and Lifestyle in Prostate Cancer Patients
  • Serdar Çelik
Bull Urooncol 2015; 14: 88-93 DOI: 10.4274/uob.307
What is the best cutoff value of PSA in detection of prostate cancer
  • Hakan Gemalmaz
Bull Urooncol 2012; 11: 92-95
Relationship Between Human Papilloma Virus and Bladder Cancer
  • Osman İnci
  • Ebru Taştekin
  • Hakan Akdere
Bull Urooncol 2017; 16: 92-94 DOI: 10.4274/uob.556
Which Treatment Should We Prefer for High-Risk Nonmuscle Invasive Bladder Cancer? Early Cystectomy or Bladder Sparing?
  • Ali Furkan Batur
  • Sinan Sözen
Bull Urooncol 2014; 13: 93-98 DOI: 10.4274/UOB.07
What is the Approach to Negative Prostate Biopsies?
  • Bora İrer
  • Güven Aslan
Bull Urooncol 2015; 14: 94-96 DOI: 10.4274/uob.310
What are the New Developments in Urinary, Serum and Tissue Biomarkers in Prostate Cancer?
  • Hayrettin Şahin
  • Mehmet Çetinkaya
  • Hasan Deliktaş
Bull Urooncol 2017; 16: 95-100 DOI: 10.4274/uob.620
NON-PSA biomarkers for prostate cancer
  • Yarkın Kamil Yakupoğlu
  • Yakup Bostancı
  • Ender Özden
Bull Urooncol 2012; 11: 96-102
Surgical treatment and/or radiotherapy in high risk prostate cancer
  • Fatih Bıçaklıoğlu
  • Cenk Acar
  • Sinan Sözen
Bull Urooncol 2013; 12: 97-101
Intermittent Versus Continuous Androgen Deprivation in Patients with Metastatic Prostate Cancer: Review
  • Mehmet Yıldızhan
  • Mehmet Dündar
  • Mehmet Şirin Ertek
Bull Urooncol 2015; 14: 97-101 DOI: 10.4274/uob.315
Evaluation of the Current Situation Tissue and Serum Biomarkers in Prostate Cancer
  • Enis Kervancıoğlu
  • Murat Koşan
Bull Urooncol 2015; 14: 102-107 DOI: 10.4274/uob.320
The Approach to High Risk Bladder Cancers in The Absence of Bacillus Calmette Guérin: What should Be the Treatment and Follow Up?
  • Polat Türker
  • Levent Türkeri
Bull Urooncol 2014; 13: 103-108 DOI: 10.4274/UOB.09
Repeat prostate biopsy: who, when, how?
  • Hayrettin Şahin
Bull Urooncol 2012; 11: 103-107
New treatment options for the castration resistant prostate cancer targeting the androgen synthesis and androgen receptor
  • Yavuz Selim Süral
  • Çağ Çal
Bull Urooncol 2013; 12: 106-110
Controversies in Radical Cystectomy: Meta-Analysis and Systemic Comparison of Open Surgery with Laparoscopic and Robotic Surgery
  • Mehmet Kaynar
  • Serdar Göktaş
Bull Urooncol 2016; 15: 107-112 DOI: 10.4274/uob.542
Focal Therapy for Prostate Cancer: Current Status of HIFU
  • Tayyar Alp Özkan
  • Saadettin Eskiçorapçı
Bull Urooncol 2015; 14: 108-112 DOI: 10.4274/uob.321
Does Urinary Cytology Find the Value in the Detection and Follow-up of Urinary Bladder Cancer?
  • Kutsal Yörükoğlu
Bull Urooncol 2014; 13: 109-112 DOI: 10.4274/UOB.10
New treatment options in castration resistant prostate cancer: enzalutamide and abiraterone acetate
  • Bülent Akdoğan
Bull Urooncol 2013; 12: 111-114
Hexyl Aminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis of Patients with Non-Muscle Invasive Bladder Cancer: A Review Based on Meta-Analysis
  • Emre Tüzel
Bull Urooncol 2014; 13: 113-118 DOI: 10.4274/UOB.11
Radical Prostatectomy and Lymphadenectomy in the High-Risk Prostate Cancer: Surgical Technique, Functional and Oncologic Outcomes
  • Hayrettin Şahin
  • Hasan Deliktaş
Bull Urooncol 2015; 14: 113-119 DOI: 10.4274/uob.324
Active surveillance for localized prostate cancer
  • İlker Tınay
  • Levent Türkeri
Bull Urooncol 2012; 11: 114-118
New treatment options for the castration resistant prostate cancer: Cabazitaxel and Spileucel-T
  • Gürbüz Görümlü
  • Erdem Göker
Bull Urooncol 2013; 12: 115-117
New treatment options in castration resistant prostate cancer: denosumab, alpharadin
  • Hakan Gemalmaz
Bull Urooncol 2013; 12: 118-122
Bladder Perforation During TUR of Non Muscle Invasive Bladder Tumours: Early and Late Management
  • Deniz Arslan
Bull Urooncol 2014; 13: 119-121 DOI: 10.4274/UOB.12
Surgical technique of nerve sparing radical prostatectomy and periprostatic field anatomy
  • Ali Cansu Bozacı
  • Bülent Akdoğan
  • Haluk Özen
Bull Urooncol 2012; 11: 119-123
Treatment Approaches for Nonmetastatic Castration-Resistant Prostate Cancer
  • Mehmet Yıldızhan
  • Hakan Gemalmaz
  • Mehmet Şirin Ertek
Bull Urooncol 2015; 14: 120-127 DOI: 10.4274/uob.328
Relationship between active surveillance / watchfull waiting and quality of life in localised prostate cancer
  • İlker Çelen
  • Yasin Ceylan
Bull Urooncol 2013; 12: 123-126
Current surgical approaches in local invasive prostate cancer: urologist approach
  • Zafer Kozacıoğlu
  • Bülent Günlüsoy
Bull Urooncol 2012; 11: 124-128
How shoud PSA repalse (rising PSA) be managed after radical prostatectomy? How should treatment algorithms be shaped?
  • İlker Çelen
  • Murat Lekili
Bull Urooncol 2013; 12: 127-131
The Status of Testicular Self-Examination in the Early Diagnosis of TesticularCancer: Conjuncture in the World and in Turkey
  • Barış Kuzgunbay
Bull Urooncol 2014; 13: 127-129 DOI: 10.4274/uob.71
Active Surveillance in Prostate Cancer
  • Volkan İzol
  • Nebil Akdoğan
Bull Urooncol 2017; 16: 127-132 DOI: 10.4274/uob.820
Prostate Biopsy 2014: TRUS, MRI/TRUS Fusion? Transrectal? Transperineal?
  • Kaan Çömez
  • Ozan Bozkurt
  • Mehmet Uğur Mungan
Bull Urooncol 2015; 14: 128-135 DOI: 10.4274/uob.329
Current treatment approaches in locally advanced prostate cancer: a radiation oncologist perspective
  • Ömür Karakoyun Çelik
Bull Urooncol 2012; 11: 129-133
Radical prostatectomy indications and outcomes in the high-risk localised prostate cancer
  • Hayrettin Şahin
  • Hasan Deliktaş
Bull Urooncol 2013; 12: 132-136
Management of recurrences after radiation therapy used for curative intent in prostate cancer
  • Yılören Tanıdır
  • Levent Türkeri
Bull Urooncol 2012; 11: 134-141
Risk Factors and Etiology in Renal Cell Carcinoma
  • Ümit Gül
Bull Urooncol 2014; 13: 135-138 DOI: 10.4274/uob.78
Multiparametric MR in Prostate Cancer: General Practical Application Advices
  • Seçil Mustafa
  • Basara Işıl
  • Altay Canan
Bull Urooncol 2015; 14: 136-143 DOI: 10.4274/uob.330
Salvage radical prostatectomy for locally recurrent prostate cancer following primary radiotherapy
  • Ali Cansu Bozacı
  • Sertaç Yazıcı
Bull Urooncol 2013; 12: 137-141
Adjuvant and Neoadjuvant Targeted Therapies in Locally Advanced Renal Cell Carcinoma
  • Ozan Bozkurt
  • Ömer Demir
Bull Urooncol 2014; 13: 139-145 DOI: 10.4274/uob.82
AUA/ASTRO 2013 Guidelines for Adjuvant and Salvage Radiation Therapy After Prostatectomy: What are the Yields and the Changes?
  • Deniz Yalman
Bull Urooncol 2015; 14: 144-149 DOI: 10.4274/uob.339
An Update on Cancers of Penis
  • Ali Furkan Batur
Bull Urooncol 2014; 13: 146-152 DOI: 10.4274/uob.87
The role of surgery in renal cell carcinoma metastasis
  • Levent Mert Günay
  • Mehmet Cemil Uygur
Bull Urooncol 2013; 12: 147-150
Prostate cancer in the era of robotic surgery
  • Çag Çal
Bull Urooncol 2012; 11: 150-155
‘Nanotechnology Applications’ in the Treatment of Prostate Cancer
  • Ali Furkan Batur
  • Kerem Gencer Kutman
  • Mustafa Suat Bolat
Bull Urooncol 2015; 14: 150-155 DOI: 10.4274/uob.375
Society of Urooncology nomogram for kidney cancer – the user's manual
  • Özgür Yaycıoğlu
Bull Urooncol 2013; 12: 151-154
Risk Factors for Urothelial Cancers
  • Ümit Gül
  • Barış Kuzgunbay
Bull Urooncol 2016; 15: 154-158 DOI: 10.4274/uob.554
Genetic alterations in kidney cancer
  • Onur Tokgün
  • Hakan Akça
Bull Urooncol 2013; 12: 155-162
Immunotherapy for the treatment of castration resistant prostate cancer: sipuleucel-T
  • Güven Aslan
Bull Urooncol 2012; 11: 156-158
Active Surveillance-Factors Affecting the Treatment Decision: 3M: “Marker”, “Mapping”, “MRI”
  • Ender Özden
  • Mehmet Necmettin Mercimek
Bull Urooncol 2015; 14: 156-160 DOI: 10.4274/uob.379
New treatment stragies in metastatic castration resistant prostate cancer: Re-Docetaxel, Abiraterone asetate, Cabazitaxel, MDV 3100
  • Sıtkı Ün
  • Ferruh Zorlu
Bull Urooncol 2012; 11: 159-163
Information about Prostate Cancer for Urologist: Ga-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Scintigraphy
  • Levent Kabasakal
Bull Urooncol 2016; 15: 159-162 DOI: 10.4274/uob.616
Rising Psa After Radical Prostatectomy: Radiotherapy in High Risk Group: Early? Late?
  • Gül Alço
  • Sefik İğdem
Bull Urooncol 2015; 14: 161-164 DOI: 10.4274/uob.387
Active Surveillance in Prostate Cancer: Can We Expand the Indications?
  • Hacı Murat Akgül
  • Asgar Garayev
  • İlker Tinay
Bull Urooncol 2016; 15: 163-166 DOI: 10.4274/uob.619
Update in the management of skeletal related events for metastatic prostate cancer: Denosumab, Alfaradin
  • Serdar Çelik
  • Uğur Mungan
Bull Urooncol 2012; 11: 164-167
The significance of tertiary Gleason pattern in prostate cancer
  • H. Hüseyin Tavukçu
  • Polat Türker
Bull Urooncol 2012; 11: 168-172
Sperm preservation in patients with testicular cancer
  • Mehmet Kazım Asutay
  • İlker Tınay
  • Cem Akbal
Bull Urooncol 2013; 12: 169-172
Postchemotherapy Retroperitoneal Lymph Node Dissection
  • Burak Çıtamak
  • Bülent Akdoğan
  • Mesut Altan
  • Haluk Özen
Bull Urooncol 2014; 13: 169-175 DOI: 10.4274/uob.138
Nursing interventions in patients receiving Taxan Chemotherapy
  • Yeter Kırdal
Bull Urooncol 2012; 11: 173-177
Infertility and Sperm Cryopreservation in Patients with Testicular Cancer
  • Mustafa Emre Bakırcıoğlu
  • Bülent Alıcı
Bull Urooncol 2014; 13: 176-181 DOI: 10.4274/uob.146
F-18 fluorodeoxyglucose positron emission tomography in testicular cancer
  • Gül Gümüser
  • Feray Aras
  • Elvan Sayit Bilgin
Bull Urooncol 2012; 11: 193-195
Follow-up principles after curative treatment in renal cancer
  • Ercan Kazan
  • Hakan Gemalmaz
Bull Urooncol 2013; 12: 194-200
Chemotherapy related adverse events in patients with testicular cancer
  • Özgür Tanrıverdi
  • Bülent Karabulut
Bull Urooncol 2012; 11: 196-200
Liquid Biopsy: Circulating Tumor Cells and its Impact on Follow-up/Treatment of Prostate Cancer Patients
  • İbrahim Kulaç
Bull Urooncol 2014; 13: 196-200 DOI: 10.4274/uob.159
Renal cell cancer pathology and molecular biology
  • Burçin Tuna
Bull Urooncol 2013; 12: 201-204
Nephron Sparing Surgery for Localized Renal Tumors - Quality of Life at a Glance
  • Yilören Tanıdır
  • Ferhad Talibzade
  • Muhammed Sulukaya
Bull Urooncol 2014; 13: 201-205 DOI: 10.4274/uob.160
Testicular cancers: developments in radiotherapy
  • Şefik İğdem
  • Gül Alço
Bull Urooncol 2013; 12: 210-213
Targeted Therapies in Advanced Renal Cell Cancer
  • Sinan Karaaslan
Bull Urooncol 2015; 14: 210-213 DOI: 10.4274/uob.396
Should the treatment approach be different for incidental renal tumors? Turkey databases
  • Emre Huri
Bull Urooncol 2012; 11: 216-220
Molecular Biology in Diagnosis and Treatment of Prostate Cancer
  • Ece Konaç
  • Sinan Sözen
Bull Urooncol 2014; 13: 228-235 DOI: 10.4274/uob.194
Hemostatic agents in open partial nephrectomy
  • Kemal Ener
  • Emrah Okulu
  • Önder Kayıgil
Bull Urooncol 2012; 11: 230-233
Approach to renal cell carcinoma with vena cava and adrenal involvement and interpretation of data of Turkey by 2012
  • Mehmet İlker Gökçe
Bull Urooncol 2012; 11: 234-239
Neoadjuvant targeted therapy in renal cell carcinoma
  • Sertaç Yazıcı
  • Halil Kızılöz
  • Haluk Özen
Bull Urooncol 2012; 11: 240-245
Current Situation in the Use of 5-Alpha Reductase Inhibitors for Prostatic Diseases
  • Murat Koşan
Bull Urooncol 2014; 13: 244-246 DOI: 10.4274/uob.212
Diagnostic and Prognostic Molecular Features of Urothelial Bladder Cancer and New Treatment Approaches
  • Zafer Küçükodacı
  • Kutsal Yörükoğlu
Bull Urooncol 2015; 14: 258-270 DOI: 10.4274/uob.366
The Effects of Hormonal Therapy on Quality of Life in Prostate Cancer
  • Yusuf Şenoğlu
  • Kamil Çam
Bull Urooncol 2015; 14: 317-320 DOI: 10.4274/uob.463
Quality of Life of Patients with Advanced/Metastatic Renal Cell Carcinoma During the Treatment Period with Targeted Drugs
  • Sinharib Çitgez
Bull Urooncol 2015; 14: 321-323 DOI: 10.4274/uob.460

Bph

Statin's role on protection from the benign prostatic hyperplasia and prostate cancer
  • Eray Hasırcı
  • A. İbrahim Oğuzülgen
Bull Urooncol 2012; 11: 270-274

About Journal

Forms

Useful Links

Applications